Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 2 | Starlite/ChEMBL | References |
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 3 | Starlite/ChEMBL | References |
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 4 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 3 | 620 aa | 579 aa | 33.2 % |
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 2 | 617 aa | 638 aa | 32.5 % |
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 4 | 630 aa | 574 aa | 31.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0292 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0292 | 0.5 | 0.5 | |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.0292 | 0.5 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0292 | 0.5 | 0.5 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.0292 | 0.5 | 0.5 |
Echinococcus granulosus | serotonin transporter | 0.0292 | 0.5 | 0.5 |
Echinococcus multilocularis | serotonin transporter | 0.0292 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 0.5 | 0.5 |
Loa Loa (eye worm) | serotonin transporter b | 0.0292 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 0.5 | 0.5 |
Loa Loa (eye worm) | norepinephrine transporter | 0.0292 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Drug uptake (ADMET) | = 0.75 % ID/g | Biodistribution in iv dosed rat hypothalamus after 120 mins | ChEMBL. | 18052090 |
Drug uptake (ADMET) | = 1.22 % ID/g | Biodistribution in iv dosed rat hypothalamus after 30 mins | ChEMBL. | 18052090 |
Drug uptake (ADMET) | = 0.59 %ID | Biodistribution in iv dosed rat brain after 120 mins | ChEMBL. | 18052090 |
Drug uptake (ADMET) | = 1.23 %ID | Biodistribution in iv dosed rat brain after 30 mins | ChEMBL. | 18052090 |
Ki (binding) | = 1.4 nM | Displacement of [125I]5-iodo-2-[[2,2-[(dimethylamino)methyl]phenyl]thio]benzyl alcohol from SERT expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ki (binding) | = 1.4 nM | Displacement of [125I]5-iodo-2-[[2,2-[(dimethylamino)methyl]phenyl]thio]benzyl alcohol from SERT expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ki (binding) | = 12 nM | Displacement of [125I]-iodonisoxetine from NET expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ki (binding) | = 12 nM | Displacement of [125I]-iodonisoxetine from NET expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ki (binding) | = 299 nM | Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ki (binding) | = 299 nM | Displacement of [125I]N-(3'-iodopropen-2'yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane from DAT expressed in LLCPK1 cells | ChEMBL. | 18052090 |
Ratio (ADMET) | = 3.5 | Ratio of drug level in hypothalamus to cerebellum in rat after 30 mins | ChEMBL. | 18052090 |
Ratio (ADMET) | = 7.67 | Ratio of drug level in hypothalamus to cerebellum in rat after 120 mins | ChEMBL. | 18052090 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.